KayoThera

Kayothera is developing a novel class of oral small molecule drugs targeting the retinoid nuclear receptor pathway, a clinically validated but previously undrugged driver of adverse metabolic and oncological outcomes. Its lead program, KAYO-1732, is a development candidate for type 2 diabetes and cardiometabolic disease, with additional programs in obesity (KAYO-2000) and male contraception (KAYO-1609). The company has garnered recognition, including winning an American Diabetes Association Innovation Challenge, and is building a strong advisory and leadership team with expertise in translation and drug development.

Oral small molecule inhibitors targeting aldehyde dehydrogenase 1A (ALDH1A) enzymes to prevent the synthesis of ligands (all-trans retinoic acid) that activate the retinoid/rexinoid nuclear receptor pathways.

In diabetes and obesity, Kayothera faces competition from large, established players (e.g., Novo Nordisk, Eli Lilly) with advanced GLP-1-based therapies and other mechanisms. Its differentiation lies in a first-in-class approach targeting β-cell function for disease modification, a space with few direct competitors. In male contraception, the competitive field is less crowded but requires overcoming significant development and adoption hurdles.